H.R. 971 - Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
- Sponsor:
- Gus M. Bilirakis
- Summary:
- To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes. (by CRS)
- Status:
- The bill has been referred to committee.
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
H.R. 971 — 114th Congress (2015–2016)
- Summary
- To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes. (by CRS)
- Learn More
- At OpenCongress
- Title
- To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes.
- Other Titles
- Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
- Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
- Sponsor
- Gus M. Bilirakis
- Co-Sponsors
- Brad Ashford
- G. K. Butterfield
- Rodney Davis
- Michael G. Fitzpatrick
- Jeff Fortenberry
- Rodney P. Frelinghuysen
- Christopher P. Gibson
- Sam Graves
- Glenn Grothman
- Alcee L. Hastings
- Jared Huffman
- Leonard Lance
- Michael T. McCaul
- Cathy McMorris Rodgers
- Richard B. Nugent
- Erik Paulsen
- Bruce Poliquin
- Mike Quigley
- Dana Rohrabacher
- Steve Scalise
- Christopher H. Smith
- Subjects
- Health
- Administrative law and regulatory procedures
- Administrative remedies
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Food and Drug Administration (FDA)
- Government information and archives
- Intellectual property
- Prescription drugs
- Related Bills
- Major Actions
Introduced 2/13/2015 Referred to Committee - Bill History
-
There have been no votes on this bill.
Action Date Description Introduced 2/13/2015 2/13/2015 Referred to the House Committee on Energy and Commerce. 2/13/2015 Introduced in House 2/20/2015 Referred to the Subcommittee on Health. Number Sponsor Date Offered Status
Total contributions given to House members from interest groups that…
supported this bill
Contributions data source: OpenSecrets.org